Pancreatic Cancer Research

ResearcherOntario Institute for Cancer ResearchActive in the last 2 years

Sandra Elisabeth Fischer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8859-4525; OpenAlex author ID A5081545818. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
108
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: 6 papers · 2021: 4 papers · 2022: 6 papers · 2023: 3 papers · 2024: none · 2025: 4 papers · 2026: 1 paper

Papers 27

  1. Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer. Co-author DOI 10.3389/frai.2026.1873681↗
  2. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  3. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  4. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  5. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  6. Hourglass, a rapid analysis framework for heterogeneous bioimaging data, identifies sex disparity in IL-6/STAT3-associated immune phenotypes in pancreatic canc… Co-author DOI 10.1002/path.6199↗
  7. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
  8. Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. Co-author DOI 10.1136/jclinpath-2021-207781↗
  9. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-022-09057-y↗
  10. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-22-1272↗
  11. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
  12. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo-22-86↗
  13. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.860767↗
  14. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? Co-author DOI 10.6004/jnccn.2021.7107↗
  15. Spatially confined sub-tumor microenvironments in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.09.022↗
  16. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Last author DOI 10.1038/s41598-021-94544-3↗
  17. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  18. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  19. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  20. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  21. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Co-author DOI 10.1158/0008-5472.can-19-1523↗
  22. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-2803↗
  23. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-19-3724↗
  24. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1439↗
  25. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Co-author DOI 10.1016/j.ccell.2018.12.010↗
  26. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. First author DOI 10.1158/1078-0432.ccr-17-2994↗
  27. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 26 shared papers, 2018–2026 · strength 3.02
  2. Jennifer Jane Knox · 23 shared papers, 2018–2026 · strength 2.69
  3. Grainne Mary O'Kane · 23 shared papers, 2018–2026 · strength 2.68
  4. Robert C. Grant · 21 shared papers, 2018–2026 · strength 2.51
  5. Faiyaz Notta · 19 shared papers, 2018–2026 · strength 2.24
  6. George Zogopoulos · 15 shared papers, 2019–2025 · strength 1.52
  7. Yifan Wang · 11 shared papers, 2020–2025 · strength 1.15
  8. Barbara T. Grünwald · 9 shared papers, 2020–2025 · strength 1.05
  9. Daniel John Renouf · 7 shared papers, 2020–2025 · strength 0.83
  10. Rama Khokha · 7 shared papers, 2020–2023 · strength 0.78
  11. Spring Holter · 7 shared papers, 2018–2025 · strength 0.75
  12. Raymond Jang · 5 shared papers, 2021–2025 · strength 0.75
  13. Ayelet Borgida · 8 shared papers, 2019–2022 · strength 0.68
  14. Erica S. Tsang · 4 shared papers, 2025 · strength 0.65
  15. Michelle Chan‐Seng‐Yue · 5 shared papers, 2019–2025 · strength 0.52
  16. David F. Schaeffer · 5 shared papers, 2020–2025 · strength 0.50
  17. Kyaw Lwin Aung · 4 shared papers, 2018–2025 · strength 0.50
  18. Joan Miguel Romero · 5 shared papers, 2019–2025 · strength 0.49
  19. Fieke E. M. Froeling · 4 shared papers, 2020–2025 · strength 0.47
  20. David Arthur Tuveson · 4 shared papers, 2020–2025 · strength 0.47
  21. Kai Duan · 3 shared papers, 2021–2025 · strength 0.46
  22. James Biagi · 4 shared papers, 2020–2023 · strength 0.43
  23. Sheron Perera · 3 shared papers, 2022–2025 · strength 0.41
  24. Joanna M. Karasinska · 4 shared papers, 2020–2025 · strength 0.41
  25. James Thomas Topham · 4 shared papers, 2020–2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.